Wednesday, July 8, 2026

pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA

Vera Therapeutics

VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropat

4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140
Clinical program

Atacicept

Phase 3 · small molecule · Lupus Nephritis (LN)

Atacicept for Lupus Nephritis (LN) is a Phase 3 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

← All Vera Therapeutics projects Phase 3 small molecule terminated

Internal code VT-001-0070

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Vera Therapeutics
Phase
Phase 3
Modality
small_molecule
Indication
Lupus Nephritis (LN)
Status
terminated
Trials
1

Clinical trials